TSHR; | |
GABBR1; | |
FFAR1; FFAR4; | |
GAA; | |
GLA; FAAH; TDP1; BLM; CDA; TERT; HPGD; ALOX15; | |
GABRR1; | |
FLT3; | |
PPARA; PPARD; PPARG; | |
TLR2; | |
HIF1A; TP53; NFKB1; | |
KMT2A; | |
SLC22A8; SLC22A6; SLC6A11; SLC6A1; SLC28A1; SLC28A3; | |
CREB1; LMNA; FABP5; FABP2; FABP4; FABP3; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | CREB1 | Cyclic AMP-responsive element-binding protein 1 | P16220 | CHEMBL5587 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.741E-07 | 1.307E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.998E-07 | 1.403E-04 | ALOX15, CREB1, FABP4, HIF1A, KMT2A, SLC6A1, TERT, TP53 |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 5.536E-07 | 3.091E-04 | CREB1, FABP3, FFAR1, PPARG, TLR2 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.044E-06 | 8.560E-04 | HIF1A, LMNA, PPARD, TERT, TP53 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.113E-06 | 8.680E-04 | FFAR1, FFAR4, FLT3, GABBR1, GABRR1, SLC22A6, SLC22A8, SLC28A1, SLC28A3, SLC6A1, SLC6A11, TLR2, TSHR |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.357E-06 | 1.260E-03 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.972E-06 | 1.442E-03 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0045834; positive regulation of lipid metabolic process | 4.671E-06 | 1.589E-03 | CREB1, FABP3, FLT3, PPARA, PPARG |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 8.471E-06 | 2.635E-03 | CREB1, PPARA, TERT |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 9.923E-06 | 3.001E-03 | FABP3, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.108E-05 | 3.160E-03 | BLM, FLT3, HPGD, NFKB1, PPARG, SLC22A6, SLC6A1, TLR2, TP53 |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.141E-05 | 3.160E-03 | HIF1A, TERT, TP53 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.190E-05 | 3.160E-03 | SLC28A1, SLC28A3 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.190E-05 | 3.160E-03 | SLC28A1, SLC28A3 |
BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.389E-05 | 3.601E-03 | CREB1, HPGD, NFKB1, SLC22A8, SLC6A1, TLR2, TP53 |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.697E-05 | 4.152E-03 | HIF1A, PPARD, TP53 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.727E-05 | 4.178E-03 | ALOX15, PPARA, PPARD, TP53 |
MF | GO:0005488; binding | GO:0035035; histone acetyltransferase binding | 2.152E-05 | 5.094E-03 | CREB1, HIF1A, TP53 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.257E-05 | 5.285E-03 | BLM, CDA, FLT3, GLA, HPGD, KMT2A, NFKB1, SLC22A6, TERT |
MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 2.377E-05 | 5.392E-03 | SLC6A1, SLC6A11 |
MF | GO:0005488; binding | GO:0043565; sequence-specific DNA binding | 3.234E-05 | 6.779E-03 | BLM, CREB1, HIF1A, KMT2A, NFKB1, PPARA, PPARD, PPARG, TERT, TP53 |
MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 3.829E-05 | 7.793E-03 | ALOX15, BLM, CDA, CYP2C19, CYP3A4, KMT2A, PPARA, PPARD, PPARG, TP53 |
BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 3.957E-05 | 7.905E-03 | PPARA, PPARG |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 4.471E-05 | 8.693E-03 | CREB1, PPARA, PPARG, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.996E-11 | 7.735E-09 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.246E-06 | 8.040E-05 | HPGD; KMT2A; FLT3; PPARG; TP53; NFKB1 |
hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 2.559E-05 | 8.251E-04 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.318E-05 | 8.560E-04 | CREB1; PPARG; TP53; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.056E-05 | 8.720E-04 | GABBR1; CREB1; PPARA; NFKB1; TSHR |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.104E-04 | 2.035E-03 | FLT3; PPARG; HIF1A; TP53; NFKB1; PPARD |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.419E-05 | 8.251E-04 | ALOX15; CYP3A4; CYP2C19 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.838E-04 | 2.673E-03 | CREB1; TP53; NFKB1; TLR2 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.865E-04 | 2.673E-03 | FLT3; NFKB1; PPARD |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.012E-04 | 3.886E-03 | FLT3; TP53; HIF1A |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.933E-04 | 8.130E-03 | CREB1; TP53; NFKB1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.248E-03 | 1.341E-02 | CREB1; PPARA; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.561E-03 | 1.342E-02 | CREB1; TERT; TP53; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.159E-03 | 1.674E-02 | CREB1; PPARG; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.551E-03 | 1.732E-02 | LMNA; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.206E-03 | 1.674E-02 | PPARA; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.350E-03 | 1.684E-02 | TP53; NFKB1; TLR2 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.267E-03 | 2.502E-02 | CREB1; TP53; NFKB1; TLR2 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.455E-03 | 1.342E-02 | PPARG; TP53 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 5.007E-03 | 2.755E-02 | CREB1; NFKB1; TLR2 |
hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 6.264E-03 | 2.981E-02 | CREB1; PPARG; TP53 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.197E-03 | 2.981E-02 | TP53; HIF1A; TLR2 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 5.572E-03 | 2.765E-02 | TP53; NFKB1; TLR2 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.394E-03 | 2.981E-02 | CREB1; TP53; NFKB1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.557E-03 | 1.342E-02 | GAA; GLA |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.112E-03 | 2.502E-02 | CREB1; NFKB1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.339E-03 | 2.755E-02 | FABP4; TSHR |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.633E-03 | 2.343E-02 | CDA; CYP3A4 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 5.155E-03 | 2.755E-02 | NFKB1; TLR2 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.346E-03 | 2.981E-02 | TP53; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 7.132E-03 | 2.981E-02 | NFKB1; TLR2 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.508E-03 | 2.981E-02 | ALOX15; CYP2C19 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.005E-03 | 3.029E-02 | CYP3A4; CYP2C19 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.924E-03 | 3.029E-02 | TP53; NFKB1 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 8.230E-03 | 3.029E-02 | PPARA; NFKB1 |
hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 8.459E-03 | 3.029E-02 | CREB1; TSHR |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 8.924E-03 | 3.029E-02 | NFKB1; TLR2 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.663E-02 | 4.566E-02 | GABBR1; GABRR1; TSHR |
hsa04911 | Insulin secretion_Homo sapiens_hsa04911 | 1.195E-02 | 3.843E-02 | CREB1; FFAR1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.596E-02 | 4.566E-02 | GABBR1; CREB1 |
hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 1.360E-02 | 4.178E-02 | GABBR1; GABRR1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.222E-02 | 3.843E-02 | TP53; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 8.459E-03 | 3.029E-02 | SLC22A8; CYP3A4 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.657E-02 | 4.566E-02 | CREB1; PPARA |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.626E-02 | 4.566E-02 | NFKB1; TLR2 |
hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.657E-02 | 4.566E-02 | FAAH; GABRR1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.115E-02 | 3.689E-02 | CYP3A4; CYP2C19 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.719E-02 | 4.610E-02 | HIF1A; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.815E-02 | 4.683E-02 | NFKB1; TLR2 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.946E-02 | 4.922E-02 | CREB1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.751E-02 | 4.610E-02 | NFKB1; TLR2 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.013E-02 | 4.993E-02 | ALOX15; CYP2C19 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CDA; TP53; FLT3; TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; TERT |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
C00-D49: Neoplasms | Liver cancer | C22 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; FLT3; FLT3; NFKB1; TLR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
C00-D49: Neoplasms | CLL | NA | FLT3 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
C00-D49: Neoplasms | AML | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; TERT |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2; TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
NA: NA | Dyslipidemia | NA | PPARD |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; TERT |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |